Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study

ELKRIEF, Laure, et al.

Abstract

In patients with idiopathic noncirrhotic portal hypertension (INCPH), data on morbi-mortality of abdominal surgery are scarce. We retrospectively analyzed the charts of patients with INCPH undergoing abdominal surgery within the VALDIG network. Forty-four patients with biopsy-proven INCPH were included. Twenty-five (57%) patients had ≥1 extrahepatic conditions related with INCPH and 16 (36%) had a history of ascites. Forty-five procedures were performed, including 30 minor and 15 major. Nine (20%) patients had ≥1 Dindo-Clavien grade ≥3 complication within 1 month after surgery. Sixteen (33%) patients had ≥1 portal hypertension related complication within 3 months after surgery. Extrahepatic conditions related with INCPH (p=0.03) and history of ascites (p=0.02) were associated with portal hypertension related complications within 3 months after surgery. Splenectomy was associated with development of portal vein thrombosis after surgery (p=0.01). Four (9%) patients died within 6 months after surgery. Six-month cumulative risk of death was higher in patients with serum creatinine ≥100 μmol/L at surgery (33%, vs. […]

Reference

ELKRIEF, Laure, et al. Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study. Hepatology, 2019

DOI : 10.1002/hep.30628
PMID : 30924941
Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study

Laure Elkrief1,2*, José Ferrusquia-Acosta3, Audrey Payance4, Lucile Moga5, Luis Tellez6, Michael Praktiknjo7, Bogdan Procopet8, Oana Farcau9, Victor De Lédinghen10, Rustam Yuldashev11, Nicolas Tabchouri12, Louise Barbier12, Jérôme Dumortier13, Benjamin Menahem14, Marta Magaz3, Virginia Hernández-Gea3, Agustín Albillos6, Jonel Trebicka7, Laurent Spahr2, Andrea De Gottardi9, Aurélie Plessier4, Dominique Valla4, Laura Rubbia-Brandt15, Christian Toso1,16, Christophe Bureau5, Juan-Carlos García-Pagan3, Pierre-Emmanuel Rautou4,17,18

Laure Elkrief1,2* laure.elkrief@hcuge.ch
José Ferrusquia-Acosta3 jaferrus@clinic.cat
Audrey Payance4 Audrey.payance@aphp.fr
Lucile Moga5 Lucile.moga@gmail.com
Luis Tellez6 luistevilla@gmail.com
Michael Praktiknjo7 Michael.Praktiknjo@ukbonn.de
Bogdan Procopet8 bogdanprocopet@gmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.30628
This article is protected by copyright. All rights reserved.
Oana Nicoara Farcau\textsuperscript{8} \hspace{1cm} oana.farcau@gmail.com

Victor De Lédinghen\textsuperscript{10} \hspace{1cm} victor.deledinghen@chu-bordeaux.fr

Rustam Yuldashev\textsuperscript{11} \hspace{1cm} Rustam0511@yahoo.com

Nicolas Tabchouri\textsuperscript{12} \hspace{1cm} nicolastabchouri@gmail.com

Louise Barbier\textsuperscript{12} \hspace{1cm} Louise.barbier@chu-tours.fr

Jérôme Dumortier\textsuperscript{13} \hspace{1cm} Jerome.dumorier

Benjamin Menahem\textsuperscript{14} \hspace{1cm} Menahem-b@chu-caen.fr

Marta Magaz\textsuperscript{3} \hspace{1cm} MMAGAZ@clinic.cat

Virginia Hernández-Gea\textsuperscript{3} \hspace{1cm} VIHERNANDEZ@clinic.cat

Agustin Albillos\textsuperscript{6} \hspace{1cm} agustin.albillos@uah.es

Jonel Trebicka\textsuperscript{7} \hspace{1cm} Jonel.trebicka@ukbonn.de

Laurent Spahr\textsuperscript{2} \hspace{1cm} Laurent.spahr@hcuge.ch

Andrea De Gottardi\textsuperscript{9} \hspace{1cm} Andrea.degottardi@gmail.com

Aurélie Plessier\textsuperscript{4} \hspace{1cm} Aurelie.plessier@aphp.fr

Dominique Valla\textsuperscript{4} \hspace{1cm} Dominique.valla@aphp.fr

Laura Rubbia-Brandt\textsuperscript{15} \hspace{1cm} Laura.rubbia-brandt@hcuge.ch

Christian Toso\textsuperscript{1,16} \hspace{1cm} Christian.toso@hcuge.ch

Christophe Bureau\textsuperscript{5} \hspace{1cm} Bureau.c@chu-toulouse.fr

Juan-Carlos Garcia-Pagan\textsuperscript{3} \hspace{1cm} jcgarcia@clinic.cat

Pierre-Emmanuel Rautou\textsuperscript{3,17,18} \hspace{1cm} perautou@yahoo.fr

This article is protected by copyright. All rights reserved.
1 Service de Transplantation, Hôpitaux Universitaires de Genève, Geneva, Switzerland
2 Service d’Hépato-gastroentérologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
3 Hepatic Hemodynamic Laboratory, European Reference Network for rare liver disorders. Liver Unit. Hospital Clinic. IDIBAPS and CIBERehd. Barcelona, Spain
4 Service d’Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, DHU Unity, Pôle des Maladies de l’Appareil Digestif, Hôpital Beaujon, AP-HP, Clichy, France
5 Service d’Hépato-gastro-entérologie, CHU Toulouse, Toulouse, France
6 Departamento de Gastroenterología y Hepatología Hospital Universitario Ramon y Cajal, Madrid, Spain
7 Laboratory for Liver Fibrosis and PortalHypertension, Universitätsklinikum Bonn, Germany
8 Department of Gastroenterology, 3rd Medical Clinic, University of Medicine and Pharmacy “Iuliu Hatieganu”. Regional Institute of Gastroenterology and Hepatology “O Fodor”, Cluj-Napoca, Romania
9 Department of Visceral Surgery and Medicine Intelspital, Bern, Switzerland
10 Service d’Hépato-gastroentérologie, Hôpital Haut-Lévêque, Bordeaux, France
11 Republican Specialized Scientific Practical Medical Center of Pediatrics, Tashkent, Uzbekistan
12 Service de Chirurgie Digestive, oncologique, endocrinienne et transplantation hépatique et FHU SUPORT, Hôpital Trousseau, Tours, France
13 Department of Digestive Diseases, Hospices Civils de Lyon, Hôpital Edouard Herriot, Université Claude Bernard Lyon 1, Lyon, France
14 Department of Digestive Surgery, University Hospital of Caen, Caen, France
15 Service de pathologie Clinique, Hôpitaux Universitaires de Genève, Geneva, Switzerland

This article is protected by copyright. All rights reserved.
Key words: cirrhosis; vascular liver disease, portal vein thrombosis, transjugular intrahepatic portosystemic shunt

FOOTNOTE PAGE

Contact information

Dre Laure Elkrief
Service de Transplantation
Hôpitaux Universitaires de Genève
Rue Gabrielle Perret-Gentil 4
1205 Genève, Switzerland
Tel: +41 79 553 37 04
laure.elkrief@hcuge.ch

Prof Pierre-Emmanuel Rautou
Service d’Hépatologie, Hôpital Beaujon
100 boulevard du General Leclerc,
92100 Clichy, France
Tel: +331 40 87 50 91, Fax +331 40 87 44 35
Mail: pierre-emmanuel.rautou@inserm.fr
List of abbreviations:
ASA, American Society of Anesthesiology; CI, Confidence Interval; HR, Hazard ratio ratio; HIV, Human Immunodeficiency virus; INCPH, Idiopathic noncirrhotic portal hypertension; IQR, interquartile range; PVT, Portal Vein Thrombosis TIPSS, Transjugular Intrahepatic portosystemic shunt;

Financial support: This study was conducted without any financial support.

The Romanian Register of idiopathic noncirrhotic portal hypertension is funded by UEFISCDI, Ministry of Education of Romania (PN-III-P1-PD-2016-0689)

Acknowledgements: We thank Nicolas Drilhon, Héloïse Giudicelli, Marie Lazareth, Djalila Rezigue, Shantha Valainathan and Kamal Zekrini for their help in identifying the patients and collecting the data and Prof. Valérie Paradis for reviewing liver biopsy samples.

Abstract
In patients with idiopathic noncirrhotic portal hypertension (INCPH), data on morbi-mortality of abdominal surgery are scarce. We retrospectively analyzed the charts of patients with INCPH undergoing abdominal surgery within the VALDIG network. Forty-four patients with biopsy-proven INCPH were included. Twenty-five (57%) patients had ≥1 extrahepatic conditions related with INCPH and 16 (36%) had a history of ascites. Forty-five procedures were performed, including 30 minor and 15 major. Nine (20%) patients had ≥1 Dindo-Clavien grade ≥3 complication within 1 month after surgery. Sixteen (33%) patients had ≥1
portal hypertension related complication within 3 months after surgery. Extrahepatic conditions related with INCPH (p=0.03) and history of ascites (p=0.02) were associated with portal hypertension related complications within 3 months after surgery. Splenectomy was associated with development of portal vein thrombosis after surgery (p=0.01). Four (9%) patients died within 6 months after surgery. Six-month cumulative risk of death was higher in patients with serum creatinine ≥100 μmol/L at surgery (33%, vs. 0%, p<0.001). An unfavorable outcome (i.e. either liver or surgical complication or death) occurred in 22 (50%) patients and was associated with presence of extra-hepatic conditions related with INCPH, history of ascites and serum creatinine ≥100 μmol/L: Five percent of the patients with none of these features had an unfavorable outcome, vs. 32% and 64% when one or ≥2 features were present, respectively. Portal decompression procedures prior to surgery (n=10) were not associated with post-operative outcome. **Conclusion.** Patients with INCPH are at high-risk of major surgical and portal hypertension related complications when they harbor extrahepatic conditions related with INCPH, history of ascites or increased serum creatinine.

*Idiopathic noncirrhotic portal hypertension (INCPH) is a heterogeneous group of rare diseases causing portal hypertension and characterized by the absence of cirrhotic modification of the liver parenchyma and the patency of portal and hepatic veins. In Europe, INCPH accounts for less than 2% of the indications for liver biopsies (1,2). Liver histological lesions found in patients with INCPH include oblitative portal venopathy, hepatoporal sclerosis, nodular regenerative hyperplasia and incomplete septal cirrhosis (3). INCPH has been associated with various conditions including thrombophilia, hematologic malignancies, human immunodeficiency virus (HIV) infection, genetic and immunological disorders (4,5). Patients with INCPH may develop portal hypertension related complications, but usually have preserved liver function.*
Patients with chronic liver diseases may require abdominal surgery for indications related to their liver disease (e.g. splenectomy or parietal surgery), or unrelated. Most available data on the risk of surgery in patients with liver disease pertains to cirrhosis, where post-operative morbidity and mortality are influenced by liver dysfunction and degree of portal hypertension (6–9), type of surgery (10,11) and comorbidities (9). Given the link between portal hypertension and post-operative outcome (11), portal decompression has been proposed to facilitate abdominal surgery and improve outcome, although reported results are contrasted (12–17).

Experience regarding abdominal surgery in patients with INCPH is mostly limited to portosystemic shunt and/or splenectomy performed in adults or children from Eastern countries (5,18–20). The present study thus aimed at evaluating the outcome of patients with INCPH undergoing abdominal surgery and at assessing the impact of preoperative portal decompression procedures.

**Patients and Methods**

**Patients**

Between April 2017 and November 2017, we contacted all the centers participating in the Vascular Liver Disease Interest Group (VALDIG) or the French network for vascular liver diseases to retrospectively identify all patients with INCPH having had ≥1 abdominal surgery. Surgeries were considered only if INCPH was known prior to the procedure or diagnosed at the time of the surgery. Patients’ identification was based on local databases. The study was approved by our institutional review board (CCER 2017-01219) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Definitions

Diagnosis of INCPH was based on the criteria proposed by the VALDIG group, after exclusion of cirrhosis (Supplementary Table 1). Histologic diagnosis of INCPH was confirmed by pathologists experts in liver diseases. Patients with portal vein thrombosis were included in this study if this thrombosis occurred after INCPH diagnosis. Patients with chemotherapy-induced non-cirrhotic portal hypertension, and/or who underwent liver resection for colorectal liver metastasis were not included, since the main liver lesion in these patients is sinusoidal obstruction syndrome, i.e. a distinct entity from INCPH (21).

Date of diagnosis of INCPH was the date the first liver biopsy demonstrating the absence of cirrhosis while signs of portal hypertension were already present, as detailed in supplementary Table 1. According to the previous reports, extra-hepatic conditions associated with INCPH were classified into the following categories (22–25): immunological disorders (autoimmune conditions, common variable immune deficiency, history of solid organ transplantation, Crohn’s disease, human immunodeficiency virus infection), recurrent abdominal infections, medication or toxins, prothrombotic state (myeloproliferative syndrome, heterozygous factor II or V Leiden, or familial history of venous thromboembolism), genetic disorders.

The following data were collected at surgery: (a) clinical features before surgery, including age, gender, American Society of Anesthesiology (ASA) class (26), age-adjusted Charlson comorbidity index (the Charlson Comorbidity index is a weighted index that takes into account the number and the seriousness of comorbid diseases by assigning points for certain illnesses (27); the age-adjusted Charlson comorbidity index assigns an additional point for each decade of life after 50 years of age), clinical, laboratory, imaging and endoscopic features; (b) surgical data, including indication, type of surgery, planned or emergency procedure, laparoscopy or laparotomy. Major surgery was defined as laparotomy with operative intervention on a visceral organ (9). History of ascites was defined as a previous ascites that was controlled with diuretics at the time of surgery, or clinically.
detectable ascites at surgery. Portal decompression intervention before surgery included TIPSS placement or surgical portosystemic shunt. Patients in whom surgical portosystemic shunt was the indication for surgery were not included.

Follow-up
Duration of follow-up was calculated from the date of surgery. End-points were pre-specified before data collection (Supplementary Table 2). Postoperative complications were defined as any event occurring within one month after surgical intervention, and was categorized according Dindo-Clavien classification. (28) Portal hypertension-related complications were defined as any of decompensation ascites, hepatic encephalopathy, significant portal hypertension related bleeding (29), acute kidney injury, or spontaneous bacterial peritonitis occurring within 3 months after surgical intervention (Supplementary Table 2). Decompensation of ascites was defined as follows: (i) in patients without ascites, onset of clinically detectable ascites, confirmed by ultrasonography; (ii) in patients with previous ascites not requiring paracentesis, ascites requiring two or more paracenteses within 3 months following surgery, or requiring a TIPSS. Post-operative death was defined as death occurring within 6 months after surgical intervention. Finally, an unfavorable outcome was defined either post-operative grade ≥3 complication according to Dindo-Clavien classification within one month after surgery, or portal-hypertension related complications within 3 months after surgery, or death within 6 months after surgery.

In order to evaluate the influence of portal decompression on post-operative outcome, we compared the occurrence of complications between patients who had or not a history of portal decompression procedure, i.e. TIPSS placement or surgical portosystemic shunt, performed before abdominal surgery.
Controls

We compared 6-month post-operative cumulative risk of death in patients with INCPH with that of patients with cirrhosis who had abdominal surgery, selected from a recently published cohort (17). Two patients with cirrhosis were matched with one patient with INCPH according to the presence of ascites at surgery (i.e. either clinically detectable ascites before TIPS placement or history of ascites at the time of surgery (i.e. previous ascites controlled with diuretic therapy at surgery, or clinically detectable ascites at surgery).

We also compared 3-year liver transplantation-free survival of patients with INCPH who had abdominal surgery, i.e. patients from the present cohort, with that of patients with INCPH who did not undergo abdominal surgery, prospectively included between January 2011 and June 2018 at the liver hemodynamic unit at Beaujon Hospital (Clichy, France). Diagnosis of INCPH was based on the criteria proposed by the VALDIG group, after exclusion of cirrhosis (Supplementary Table 1). Among the 101 patients meeting these criteria, 7 were excluded because they were referred to the liver hemodynamic unit for evaluation before liver transplantation, 9 because follow-up data were not available, and 3 because they were already included in the present study.

Statistical analysis

Results are presented as median (interquartile range (IQR)) or absolute number (percentage). Comparisons between quantitative variables were performed using the T test or Mann-Whitney test for normally and non-normally distributed variables, respectively. Shapiro–Wilk test was used to determine whether or not the distribution of continuous variable was normal. Comparisons between categorical variables were performed using the Chi-square or Fisher exact test, when appropriate. Univariate Cox regression analyses were performed to determine factors associated with post-operative complication grade ≥3 within one month after surgery, portal-hypertension related complications within 3 months after
surgery, death within 6 months after surgery or unfavorable outcome after surgery. Factors included in the univariate analysis were pre-specified based on their previous identification as prognostic factors in patients with cirrhosis undergoing surgery and/or in patients with INCPH. These factors included age-adjusted Charlson comorbidity index (30), extrahepatic condition associated with INCPH (23–25), history of ascites at the time of surgery (i.e. previous ascites controlled with diuretic therapy at surgery, or clinically detectable ascites at surgery) (23–25,31), varices needing treatment (i.e. medium/large esophageal and/or gastric varices or history of variceal bleeding or history of endoscopic band ligation and/or glue) (11,31), portal vein thrombosis at surgery (22), serum bilirubin at surgery (8,9,31,32), serum creatinine at surgery (8,9,24,31,33), major surgery (9,10), and emergency procedures (6–8,32). Although MELD and Child-Pugh scores are known to be associated with postoperative outcome after abdominal surgery in patients with cirrhosis (9,32,33), we deliberately chose not to insert these scores, but rather serum creatinine and bilirubin, since 6 patients were treated with vitamin K antagonists and since serum albumin concentration was available in only 34/44 patients. We did not analyze HVPG because HVPG is not a good reflection of portal hypertension in patients with INCPH (25,34).

In order to assess the influence of portal decompression on postoperative outcome, we performed additional analyses including portal decompression in the Cox regression analysis. Hazard ratio (HR) for Cox logistic regression were provided with their 95% confidence interval (CI). Cumulative risk of death was assessed according to the Kaplan–Meier method and compared using the log-rank test. All tests were two-sided and p ≤0.05 was considered to be significant. Data handling and analysis were performed with SPSS 21.0 (SPSS Inc, Chicago, IL, USA).
Results

Patients’ characteristics at surgery

Between 2002 and 2017, 45 surgical interventions were performed in 44 patients from 10 centers participating in the VALDIG network or the French network for vascular liver disease (Supplementary Table 4). Their characteristics at the time of surgery are presented in Table 1. INCPH was diagnosed at the time of surgery in 8 (18%) patients. In the 36 other patients, median time between INCPH diagnosis and surgery was 26 (6-50) months. Prevalence of signs of portal hypertension at INCPH diagnosis, namely ascites and gastroesophageal varices, was similar between the 8 patients in whom INCPH was diagnosed at surgery and the 36 patients with known INCPH at surgery (data not shown). At least one extra-hepatic condition associated with INCPH was present in 25 (57%) patients, including 23 with either immunological disorder or HIV infection. Fourteen (32%) had 2 or more conditions. Age-adjusted Charlson comorbidity index was ≥3 in 35 (80%) patients, indicating that significant comorbidities were common. Liver function was preserved in the majority of the patients, since 32 (73%) patients had serum bilirubin ≤ 34 µmol/L, 32 (73%) had INR < 1.5, none had hepatic encephalopathy and only 7 (16%) patients had clinically detectable ascites, including 2 (5%) with tense ascites at surgery (Table 1). Eleven (25%) patients had serum creatinine ≥100 µmol/L before surgery. HVPG was measured in 28 (64%) patients. Median (IQR) HVPG was 9 (6-15) mm Hg.

Sixteen (36%) patients were treated with anticoagulants before surgery, including low molecular weight heparin (n=7), non-fractioned heparin (n=1), fondaparinux (n=1), rivaroxaban (n=1) and vitamin K antagonists (n=6). Among these 16 patients, anticoagulation was stopped before surgical intervention in 8 patients. Thus, 8 (18%) patients were still treated with anticoagulation therapy at the date of surgery. Seven (16%) patients were treated with antiplatelet agents before surgery, including aspirin (n=6) and clopidogrel (n=1). Among these 7 patients, antiplatelet agents had been stopped before
surgical intervention in 2 patients. Thus, 5 (11%) patients were still treated with antiplatelet agents at the date of surgery.

Type of, and indications for abdominal surgery are detailed in Table 2. One patient underwent 2 different operations (emergency surgery for perforated gastric ulcer suture, followed by elective abdominoplasty, 2 years later). There were 15 (33%) major and 30 (67%) minor interventions (including 12 laparoscopic surgeries). Eleven interventions (24%) were emergency surgeries, whereas the 34 (76%) remaining were planned interventions. Among the 7 patients with elevated serum creatinine concentration (i.e. serum creatinine ≥100 µmol/L) and a history of ascites at surgery, 3 had major surgery and 2 others had surgery in emergency (Supplementary Table 5). In the peri-operative period, red blood cells and platelets were transfused in 11 (24%) and 8 (18%) patients, respectively.

Post-operative complications within 1 month after surgery
According to the Dindo-Clavien classification, 61 post-operative complications occurred in 31 (70%) patients within 1 month after surgery (Table 3). In median, 2 (1.0-3.0) complications occurred per patient. In 9 (20%) patients, post-operative complications were classified as grade ≥3 or more according to the Dindo-Clavien classification. Ten (22%) patients developed post-operative bleeding, including 4 classified as grade ≥3 according to the Dindo-Clavien classification. Three patients required an intervention (surgical or radiological), and 2 required transfusion of red blood cells and/or platelet units (Supplementary Table 6). Antiplatelet agents at surgery (3/10 (30%) vs. 2/35 (6%), p=0.03), as well as anticoagulation (5/10 (50%) vs. 3/35 (9%), p=0.003) were the only factors associated with post-operative bleeding among those tested, as indicated in Table 1. Platelet count at surgery was similar in patients with or without post-operative bleeding (p=0.6).

Nineteen post-operative infections occurred in 15 (33%) patients, including only one classified as grade ≥3 according to Dindo-Clavien classification. No patient developed post-operative liver failure.

This article is protected by copyright. All rights reserved.
As shown in Table 4, none of the pre-specified factors were significantly associated with the development of at least one grade ≥3 complications according to the Dindo-Clavien classification.

**Portal hypertension related complications within 3 months after surgery**

Twenty-seven portal hypertension related complications occurred in 16 (36%) patients within 3 months after surgery. Median time between surgery and occurrence of such complications was 6 (1-17) days. Decompensation of ascites, occurring in 12 (26%) patients, was the most frequent of such complications. In two patients, a TIPSS was placed for refractory ascites, 5.9 and 7.5 months after surgery, respectively. Hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis and acute kidney injury occurred in 3 (7%), 2 (4%), 3 (7%) and 7 (16%) patients, respectively. One patient had TIPSS placement for refractory variceal bleeding 14 days after surgery. Resolution of portal hypertension related complication occurred in 15 out of the 16 patients, after 26 (10-59) days. One patient died 5.7 months after surgery (Patient 7, Table 5). Length of hospital stay was significantly longer in patients who developed portal hypertension related complications than in those who did not (30 (6-45) days vs. 6 (3-16) days, p=0.002).

Factors associated with the occurrence of at least one portal hypertension related complication included a history of ascites and extra-hepatic conditions associated with INCPH. Serum creatinine at surgery was not associated with the occurrence of at least one portal hypertension related complication (Table 4).

**Portal vein thrombosis after surgery**

Five (11%) patients developed *de novo* portal vein thrombosis (PVT), 28 (range 1-45) days after surgical intervention (Supplementary Table 7). Interestingly, 3 out of these 5 surgeries were splenectomies, whereas 2 had other surgical interventions. PVT occurred in 3 out of the 6 patients (50%) who had splenectomy vs. 2 out of the 39 (5%) who had another surgical intervention (p=0.01). Overall, complete recanalization was observed in 3 of 5 patients. Two
out of the 3 patients received anticoagulation, and complete recanalization was observed after 4 and 5.5 months, respectively. The third patient did not receive anticoagulation, since a TIPSS was inserted; complete recanalization was observed after 8 months.

**Death after surgery**

Thirteen (29%) patients were admitted in intensive care unit after surgery, with a median (IQR) length of stay in intensive care unit of 4 (2-7) days. Median (IQR) overall length of hospital stay was 10 (4-28) days. Four patients died within 6 months after surgery. Their characteristics are presented in Table 5. None of the patients underwent liver transplantation within the observation period.

As shown in Table 4, age-adjusted Charlson comorbidity index and serum creatinine level were associated with death within 6 months after surgery. Patients with age-adjusted Charlson comorbidity index $\geq 6$ before surgery had a 6-month cumulative risk of death of 27% vs. 0% for patients with an index below this threshold ($p=0.002$). We have previously reported that serum creatinine level higher than 100 $\mu$mol/L is associated with a poor outcome after TIPSS in patients with INCPH (25). Using this threshold here, we observed that patients with serum creatinine $\geq 100$ $\mu$mol/L had a 6-month cumulative risk of death of 33% vs. 0% for patients with serum creatinine below this threshold (Figure 1).

We compared 6-month cumulative risk of death after abdominal surgery of patients with INCPH with that of patients with cirrhosis matched according to the presence of ascites at surgery. One patient with INCPH could not be matched according to the presence of ascites, explaining why 43 patients with INCPH were compared with 86 patients with cirrhosis. Characteristics of the 86 patients with cirrhosis are shown in Supplementary Table 3. As shown in Figure 1B, 6-month cumulative risk of death was similar between the two groups.

In addition, in order to evaluate the impact of abdominal surgery on overall outcome of patients with INCPH, we compared 3-year liver transplantation-free survival of patients with INCPH who had abdominal surgery within 3 years after diagnosis of INCPH (29 patients
from the present study) with that of patients with INCPH but without abdominal surgery (n=82). As shown in Figure 1C, 3-year transplant-free survival was similar between the two groups.

**Overall post-operative unfavorable outcome**

Overall post-operative outcome was unfavorable in 22 (50%) patients. History of ascites was associated with an unfavorable outcome (Table 4). As extra-hepatic conditions related with INCPH and serum creatinine levels fell short of statistical significance and as we have previously reported that these features are associated with a poor outcome after TIPSS in patients with INCPH (25), we classified patients according to these items and to history of ascites at surgery. As shown in Figure 2, 5% of the patients with neither extra-hepatic condition associated with INCPH nor history of ascites at surgery nor serum creatinine ≥100 µmol/L had an unfavorable outcome. Only one patient without these criteria had an unfavorable outcome; this patient had post-operative bleeding after cholecystectomy, requiring reintervention under local anestheisa. By contrast, 64% of the patients with ≥2 features had an unfavorable outcome.

**Influence of portal decompression on post-operative outcome**

As shown in Figure 3, 11 patients had portal decompression prior to, or at the time of, surgery. In 1 of these patients, portosystemic shunt was the indication for surgery, with concomitant splenectomy (Table 2 and Figure 3). In the 10 remaining patients, median time between portal decompression and surgical intervention was 4.0 (0.3-44.6) months. In order to assess the effect of portal decompression on the outcome after surgery, we compared the outcome of the 10 patients who had either TIPSS or portosystemic shunt before surgery, to the 33 patients who did not (Supplementary Table 8). Except for beta-blockers, baseline characteristics did not differ between the two groups. Post-operative outcomes did not differ between patients with previous TIPSS or portosystemic shunt and those without. In patients who had a previous TIPSS or surgical portosystemic shunt, one
patient had a grade $\geq 3$ complication within one month after surgery (leakage), and 3 had at least one portal hypertension related complications within 3 months after surgery (1 decompensation of ascites, 1 decompensation of ascites and encephalopathy and 1 acute kidney injury). When included in the univariate Cox regression analysis, portal decompression was not associated with neither portal hypertension related complications (HR (95% CI) 0.746 (0.212-2.618), p=0.647) or death within 6 months after surgery (HR (95% CI) 1.153 (0.120-11.088), p=0.902). Furthermore, portal decompression was not associated with an unfavorable outcome after surgery (HR (95% CI) 0.874 (0.322-2.372), p=0.792).

Discussion
This study focusing on the outcome of patients with INCPH undergoing abdominal surgery shows that 6-month mortality after surgery was 9%, affecting patients with comorbidities and/or serum creatinine level $\geq 100$ µmol/L. Patients without extra-hepatic conditions related with INCPH, without increased serum creatinine and without a history of ascites at surgery had a favorable post-operative outcome. Although this study gathered the largest number of patients with INCPH undergoing abdominal surgery reported at present, interpretation of the results should take into account that number of patients included remained limited, that the study was retrospective, and that various surgical interventions were performed. Given the rarity of the disease, conducting a prospective study seems however not realistic.

The main information derived from this study is that mortality of patients with INCPH undergoing abdominal surgery is higher than that reported in the general population. We observed a 6-month mortality rate of 9% (95% CI 1-17%) in patients with INCPH, while in the general population, in-hospital or 1-month mortality after abdominal surgery ranges from 3% (95% CI 0.4-7%) to 12% (95% CI 7-18%) (35–37). We observed that 6-month mortality rate of patients with INCPH did not differ from that of patients with cirrhosis, matched for ascites, who underwent abdominal surgery between 2005 and 2016 (17). It should however
be noted that mortality of patients with cirrhosis in this cohort was lower than previously reported (7,10,31–33). Indeed, in patients with cirrhosis, reported mortality after surgery ranges from 7 % (95% CI 2-12%) to 30 % (95% CI 15-44%) (7,8,31,33) at 1 month, is of 30% (24-36) at 3 months and 54% (47-61) at 1 year (32). This lower mortality observed here in patients with cirrhosis may be related to a better selection of candidates for abdominal surgery, and to the fact that these procedures were performed in tertiary centers. This outcome of patients with INCPH after surgery echoes the overall survival of patients with INCPH outside the surgical setting, known to be intermediate between those of the general population and of patients with cirrhosis (23). In the present study, comorbidities were the main drivers of postoperative mortality, as death within six months after surgery was restricted to patients with age-adjusted Charlson comorbidity index ≥ 6 or with serum creatinine ≥100 µmol/L before surgery. This finding is in line with the natural history of INCPH, where half the mortality is accounted for by extrahepatic comorbidities (22–24), as well as with the outcome after TIPSS placement where mortality is associated with serum creatinine and the presence of extra-hepatic conditions associated with INCPH (25). Interestingly, transplant-free survival after INCPH diagnosis was similar in patients who did and did not undergo abdominal surgery during follow-up, suggesting that, in selected patients managed in expert centers, surgery does not have a deleterious impact on the natural history of INCPH. We did not find any association between the type of intervention and post-operative outcomes, but cannot rule out a lack of power due to the limited sample size.

The second major finding of the present study was that portal hypertension related complications, especially ascites, were the most frequent, occurring within 3 months after surgery in 36% and 26% of the patients, respectively. Portal hypertension related complications increased the length of hospital stay, and 3/16 (19%) required a TIPSS after surgery for refractory ascites or variceal bleeding. However, they were transient in most
patients. These results suggest that portal hypertension *per se*, should not be regarded as a definite contra-indication for abdominal surgery in patients with INCPH.

*De novo* PVT occurred in 5 (11%) patients after surgery. Interestingly, PVT following splenectomy was 10-fold more frequent than following other surgeries. Reported rates of PVT following splenectomy range between 17% (95% CI 13-21%) and 36% (95% CI 17-55%) in patients with cirrhosis (38,39), and are of 54% (95% CI 46-61%) in patients with benign hematologic disorders (40). In the present study, the incidence of PVT was similar to that of non-cirrhotic patients, since PVT was observed in 50% (95% CI 9-90%) of the patients with INCPH and splenectomy. Four cases of PVT were diagnosed within one month after surgery. Recanalization occurred in 60% of the patients. These findings suggest that routine ultrasound examination at 1 week, 1 month and 3 months after surgery would allow an early detection of PVT, especially after splenectomy.

Infections within 1 month after surgery were common, being observed in 34% of the patients. This figure is in the same range as estimates of post-operative infections after abdominal surgery in patients with cirrhosis and higher than in the general population [29% (95% CI 21-36%) and 13% (95% CI 12-14%), respectively, p<0.001] (41). In cirrhosis, the risk of infection is likely related to altered innate and adaptive immunity and to increased bacterial translocation (42). In patients with INCPH, susceptibility to infection may be related to portal hypertension but also to extrahepatic conditions associated with INCPH, namely immunological disorders and HIV infection. Bleeding occurred within 1 month in 10 (22%) patients and was associated with administration of anticoagulant or antiplatelet agents. This high incidence is reminiscent of the frequent bleeding episodes reported in patients with Budd-Chiari syndrome undergoing invasive procedures while receiving anticoagulation therapy (43).

In the present study, we identified a group of patients having an unfavorable outcome, namely those with extra-hepatic condition associated with INCPH, elevated serum creatinine and/or significant ascites before surgery. By contrast, only 5% of the patients with neither extra-hepatic condition associated with INCPH nor elevated serum creatinine nor significant
ascites before surgery had an unfavorable outcome. These simple features could be helpful in making a decision for abdominal surgery with due information of the patient on the risks of the intervention. Due to the retrospective and uncontrolled design of the study, we could not evaluate the survival benefit of surgery (vs. no intervention), taking into account the indication of surgery, the severity of INCPH and extrahepatic comorbidities.

In patients with cirrhosis, the experience of pre-emptive TIPSS placement before surgery is limited to small, retrospective studies (12–17). A limited number of studies compared patients with cirrhosis with preserved or moderately impaired liver function who had pre-operative TIPSS, to patients who underwent elective surgery without preoperative TIPSS. Outcome after surgery was similar between patients who had or not a preoperative TIPSS (15,17). In the present study, portal decompression was not associated with post-operative outcome after surgery. However, present findings are insufficient to draw any firm conclusion for or against preemptive portal decompression before surgery in patients with INCPH.

Indeed, TIPSS was placed as a preparation for surgery in only 4 patients; in the 5 remaining patients, TIPSS had been previously inserted for other reasons, with sometimes a broad interval of time between TIPSS insertion and surgery. Larger dedicated studies are thus needed to address this important question.

In conclusion, in this study, we observed that patients with INCPH were at high risk of major surgical and portal hypertension related complications when they harbored extrahepatic conditions related to INCPH, and/or increased serum creatinine and/or a history of ascites. Comorbidities and higher serum creatinine were significantly associated with 6-month mortality. Further studies are needed to evaluate the impact of each type of surgery on the natural history of INCPH and the influence of TIPSS on post-operative outcome.
References

1. Barge S, Grando V, Nault J-C, Broudin C, Beaugrand M, Ganne-Carrié N, et al. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. Liver Int. Off. J. Int. Assoc. Study Liver. 2016;36:1059–1066.
2. Guido M, Sarcognato S, Sonzogni A, Lucà MG, Senzolo M, Fagioli S, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int. Off. J. Int. Assoc. Study Liver. 2016;36:454–460.
3. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J. Hepatol. 2015;63:743–752.
4. Schouten JNL, Garcia-Pagan JC, Valla DC, Janssen HLA. Idiopathic noncirrhotic portal hypertension. Hepatol. Baltim. Md. 2011;54:1071–1081.
5. Khanna R, Sarin SK. Non-cirrhotic portal hypertension - diagnosis and management. J. Hepatol. 2014;60:421–441.
6. Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: Still a major surgical challenge. Surgery. 1997;122:730–736.
7. Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am. J. Surg. 2004;188:580–583.
8. Telem DA, Schiano T, Goldstone R, Han DK, Buch KE, Chin EH, et al. Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2010;8:451–457, quiz e58.
9. Risk factors for mortality after surgery in patients with cirrhosis. - PubMed - NCBI [Internet]. [cited 2018 Dec 17];Available from: https://www.ncbi.nlm-nih.gov.gate2.inist.fr/pubmed?term=gastroenterology%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Teh%5Bauthor%5D&cmd=detailssearch
10. Wong R, Rappaport W, Witte C, Hunter G, Jaffe P, Hall K, et al. Risk of nonshunt abdominal operation in the patient with cirrhosis. J. Am. Coll. Surg. 1994;179:412–416.
11. Csikesz NG, Nguyen LN, Tseng JF, Shah SA. Nationwide volume and mortality after elective surgery in cirrhotic patients. J. Am. Coll. Surg. 2009;208:96–103.
12. Azoulay D, Buabse F, Damiano I, Smail A, Ichai P, Dannaoui M, et al. Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J. Am. Coll. Surg. 2001;193:46–51.
13. Gil A, Martínez-Regueira F, Hernández-Lizoain JL, Pardo F, Olea JM, Bastarrika G, et al. The role of transjugular intrahepatic portosystemic shunt prior to abdominal tumoral surgery in cirrhotic patients with portal hypertension. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2004;30:46–52.
14. Schlenker C, Johnson S, Trotter JF. Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries. Surg. Endosc. 2009;23:1594–1598.
15. Vinet E, Perreault P, Bouchard L, Bernard D, Wassef R, Richard C, et al. Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study. Can. J. Gastroenterol. J. Can. Gastroenterol. 2006;20:401–404.
16. Kim JJ, Dasika NL, Yu E, Fontana RJ. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery. J. Clin. Gastroenterol. 2009;43:574–579.
17. Tabchouri N, Barbier L, Menahem B, Perarnau J-M, Muscari F, Fares N, et al. Transjugular Intrahepatic Portosystemic Shunt as a bridge to abdominal surgery in cirrhotic patients. J. Gastrointest. Surg. in press.
18. Sharma BC, Singh RP, Chawla YK, Narasimhan KL, Rao KL, Mitra SK, et al. Effect of shunt surgery on spleen size, portal pressure and oesophageal varices in patients with...
non-cirrhotic portal hypertension. J. Gastroenterol. Hepatol. 1997;12:582–584.
19. Pal S, Radhakrishna P, Sahni P, Pande GK, Nundy S, Chattopadhyay TK. Prophylactic surgery in non-cirrhotic portal fibrosis: is it worthwhile? Indian J. Gastroenterol. Off. J. Indian Soc. Gastroenterol. 2005;24:239–242.
20. Karagul S, Yagci MA, Tardu A, Ertugrul I, Kirmizi S, Sumer F, et al. Portosystemic Shunt Surgery in Patients with Idiopathic Noncirrhotic Portal Hypertension. Ann. Transplant. 2016;21:317–320.
21. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–439.
22. Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J. Hepatol. 2011;54:455–461.
23. Schouten JNL, Nevens F, Hansen B, Laleman W, van den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment. Pharmacol. Ther. 2012;35:1424–1433.
24. Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatol. Baltim. Md. 2014;59:2276–2285.
25. Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatol. Baltim. Md. 2016;64:224–231.
26. Keats AS. The ASA classification of physical status—a recapitulation. Anesthesiology. 1978;49:233–236.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987;40:373–383.
28. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004;240:205–213.
29. de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 2010;53:762–768.
30. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, et al. Risk Factors for Mortality After Surgery in Patients With Cirrhosis. Gastroenterology. 2007;132:1261–1269.
31. Ziser A, Plevak DJ, Wiesner RH, Rakela J, Offord KP, Brown DL. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology. 1999;90:42–53.
32. Neeff HP, Streule GC, Drognitz O, Tittelbach-Helmrich D, Spangenberg H-C, Hopt UT, et al. Early mortality and long-term survival after abdominal surgery in patients with liver cirrhosis. Surgery. 2014;155:623–632.
33. Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann. Surg. 2005;242:244–251.
34. Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut. 1987;28:260–266.
35. del Olmo JA, Flor-Lorente B, Flor-Civera B, Rodriguez F, Serra MA, Escudero A, et al. Risk factors for nonhepatic surgery in patients with cirrhosis. World J. Surg. 2003;27:647–652.
36. Wilson RJT, Davies S, Yates D, Redman J, Stone M. Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery. BJA Br. J.
37. Shaw AD, Bagshaw SM, Goldstein SL, Scherer LA, Duan M, Schermer CR, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann. Surg. 2012;255:821–829.

38. Li M-X, Zhang X-F, Liu Z-W, Lv Y. Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis. Hepatobiliary Pancreat. Dis. Int. HBPD INT. 2013;12:512–519.

39. Kawanaka H, Akahoshi T, Kinjo N, Konishi K, Yoshida D, Anegawa G, et al. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. Ann. Surg. 2010;251:76–83.

40. de'Angelis N, Abdalla S, Lizzi V, Esposito F, Genova P, Roy L, et al. Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery. 2017;162:1219–1230.

41. Pessaux P, Msika S, Atalla D, Hay J-M, Flamant Y, French Association for Surgical Research. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery: a multivariate analysis based on a prospective multicenter study of 4718 patients. Arch. Surg. Chic. Ill 1960. 2003;138:314–324.

42. Gustot T, Durand F, Lebrec D, Vincent J-L, Moreau R. Severe sepsis in cirrhosis. Hepatol. Baltim. Md. 2009;50:2022–2033.

43. Rautou P-E, Douarin L, Denninger M-H, Escolano S, Lebrec D, Moreau R, et al. Bleeding in patients with Budd–Chiari syndrome. J. Hepatol. 2011;54:56–63.
Figures’ legends.

Figure 1.

Figure 1A: Cumulative incidence of death at 6 months after abdominal surgery, according to serum creatinine before surgery

Figure 1B: Cumulative incidence of death at 6 months after abdominal surgery in 44 patients with INCPH and in 86 patients with cirrhosis matched for ascites at surgery

Figure 1C: Transplant-free survival, from date of diagnosis of INCPH, in patients undergoing or not abdominal surgery during follow-up. Each red arrows indicates an abdominal surgery. For 8/29 patients, INCPH was diagnosed at surgery (red star).

Abbreviation: INCPH, idiopathic noncirrhotic portal hypertension

Figure 2. Proportion of the patients having an unfavorable outcome after surgery according to the presence of extra-hepatic conditions associated with INCPH serum creatinine ≥100 µmol/L and/or history of ascites at surgery.

An unfavorable outcome was defined as any of post-operative complication grade ≥3 within one month after surgery, portal-hypertension related complications within 3 months after surgery or death within 6 months after surgery.

Eleven patients had neither extra-hepatic condition associated with INCPH nor serum creatinine ≥100 µmol/L nor history of ascites at surgery; 17 patients one out of the 3 features among extra-hepatic condition associated with INCPH, serum creatinine ≥100 µmol/ or history of ascites at surgery; 16 patients at least 2 of the 3 features.

Figure 3. Distribution of the patients according to the type and the indication for portal decompression.
Table 1. Characteristics of the 44 patients at surgery

| Characteristics                                      | Patients with available data | Number (percentage) or median (interquartile range) |
|------------------------------------------------------|------------------------------|-----------------------------------------------------|
| **Clinical features**                                |                              |                                                     |
| Male gender                                          | 44                           | 30 (68)                                             |
| Age, years                                           | 44                           | 53 (37-65)                                          |
| Age adjusted - Charlson comorbidity index            | 44                           | 4 (3-6)                                             |
| ASA score                                            | 44                           | 3 (2-3)                                             |
| At least one extra-hepatic condition associated with INCPH | 44                           | 25 (57)                                             |
| Immunological disorder                               |                              | 18 (41)                                             |
| HIV infection                                        |                              | 5 (11)                                              |
| Recurrent abdominal infection                         |                              | 5 (11)                                              |
| Medication or toxin                                  |                              | 5 (11)                                              |
| Prothrombotic condition                              |                              | 2 (5)                                               |
| Genetic disorder                                     |                              | 2 (5)                                               |
| At least one other cause of chronic liver disease     | 44                           | 11 (25)                                             |
| Excessive alcohol consumption                        |                              | 2 (4)                                               |
| Metabolic syndrome                                   |                              | 5 (11)                                              |
| Hepatitis C virus infection                           |                              | 4 (9)                                               |
| Diabetes mellitus                                    | 44                           | 13 (30)                                             |
| Ascites                                              | 44                           |                                                     |
| Absent                                               |                              | 28 (64)                                             |
| Controlled with diuretics                            |                              | 9 (14)                                              |
| Clinically detected                                  |                              | 7 (16)                                              |
| History of ascites *                                  | 44                           | 16 (36)                                             |
| Hepatic encephalopathy                               | 44                           | 0 (0)                                               |
| Previous variceal bleeding                           | 43                           | 18 (42)                                             |
**Treatment before surgery**

| Anticoagulation therapy | 43 | 16 (36) |
|-------------------------|----|---------|
| Antiplatelet agents     | 43 | 7 (16)  |
| Diuretic therapy        | 43 | 15 (34) |
| Beta-blockers           | 43 | 18 (41) |

**Endoscopic data**

| Gastro-esophageal varices | 42 | 10 (24) |
|---------------------------|----|---------|
| Absent                    |    | 10 (24) |
| Small                     |    | 10 (24) |
| Medium or large           |    | 22 (52) |

Varices needing treatment** 30 (71)

**Imaging data**

| Portosystemic collaterals at imaging | 43 | 25 (58) |
|--------------------------------------|----|---------|
| Spleen size, cm                      | 35 | 16 (14-20) |
| Previous splenectomy                 | 45 | 3 (7) |
| Thrombosis of the portal venous axis | 43 | 6 (14) |
| Partial occlusion                    |    | 3 (7) |
| Complete occlusion                   |    | 3 (7) |

**Laboratory data**

| Hemoglobin, g/dL | 42 | 11.8 (10.0-13.9) |
|------------------|----|-----------------|
| Leucocyte count, $\times 10^9$/L | 41 | 5.2 (3.4-10.0) |
| Platelet count, $\times 10^9$/L   | 42 | 87 (67-161) |
| INR                            | 42 | 1.13 (1.02-1.47) |
| AST, IU/L                      | 43 | 32 (25-47) |
| ALT, IU/L                      | 42 | 26 (19-37) |
| ALK, IU/L                      | 41 | 136 (77-251) |
| GGT IU/L                       | 42 | 57 (23-127) |
| Serum bilirubin, $\mu$mol/L    | 43 | 17 (12-35) |

This article is protected by copyright. All rights reserved.
Serum creatinine, μmol/L 44 79 (61-106)
Serum albumin, g/L 34 37 (31-41)
MELD score 39 9 (7-12)

*History of ascites at surgery was defined either as a previous history of ascites that was controlled with diuretics at the time of surgery, or clinically detected ascites at surgery.

** Medium/large esophageal and/or gastric varices or history of variceal bleeding or history of endoscopic band ligation and/or glue

Abbreviations: ASA, American Society of Anesthesiologists; INCPH, idiopathic noncirrhotic portal hypertension; HIV, human immunodeficiency virus; AST, Aspartate aminotransferase; ALT, alanine aminotransferase; ALK, alkaline phosphatase; GGT, gamma glutamyl transpeptidase; IU, international Unit; MELD, Model for End-Stage Liver diseases

Table 2. Type and indications for the 45 surgical interventions

| Minor surgeries                        | Open surgeries | Laparoscopic surgeries |
|----------------------------------------|----------------|------------------------|
| Abdominal wall                         | 13             | 2                      |
| Hernia repair                          | 10             |                        |
| Alfpump® implantation                  | 1              |                        |
| Abdominoplasty                         | 1              |                        |
| Surgical exploration                   | 1              |                        |
| Cholecystectomy                        | 2              |                        |
| Retroperitoneum mass excision          | 1              |                        |
| Appendicectomy                         | 1              |                        |
| Cesarean section                       | 1              |                        |

This article is protected by copyright. All rights reserved.
| Procedure                                                                 | Count |
|---------------------------------------------------------------------------|-------|
| Splenectomy                                                               | 1     |
| Colorectal surgery                                                        | 4     |
| Ileal resection (Crohn's disease)                                         | 2     |
| Appendicectomy                                                            | 2     |
| Partial liver resection                                                   | 1     |
| **Major surgeries**                                                       | 15    |
| Urologic or kidney surgery                                                | 5     |
| Renal transplantation                                                     | 2     |
| Nephrectomy                                                               | 2     |
| Renal carcinoma                                                           | 1     |
| Bleeding after renal biopsy                                               | 1     |
| Cystectomy and hysterectomy for urothelial carcinoma                     | 1     |
| Splenectomy                                                               | 5     |
| Splenectomy alone                                                         | 3     |
| Splenectomy + caudal pancreatectomy                                       | 1     |
| Splenectomy + porto-caval shunt                                          | 1     |
| Colic resection                                                           | 2     |
| Crohn's disease                                                           | 1     |
| Colorectal cancer                                                         | 1     |
| Gastric and pancreatic surgery                                            | 2     |
| Gastrectomy for gastric neoplasia                                         | 1     |
| Pancreatectomy for neuroendocrine neoplasia                               | 1     |
| Partial liver resection                                                   | 1     |
Table 3. Details on 61 surgical or post-operative complications that occurred in 31 patients within 1 month after surgery

| Type of complication          |   |
|------------------------------|---|
| **Infection**                | 19|
| Lung                         | 5 |
| Urinary tract infection      | 3 |
| Skin infection               | 3 |
| Intra-abdominal infection    | 3 |
| Cholangitis                  | 1 |
| Clostridium difficile infection | 1 |
| No source identified         | 3 |
| **Post-operative bleeding**  | 10|
| Fistula/leak                 | 5 |
| Abdominal leak               | 3 |
| Urinary leak                 | 2 |
| **Digestive complications**  | 5 |
| Vomiting                     | 2 |
| Ileus                        | 3 |
| **Cardiopulmonary**          | 8 |
| Respiratory failure          | 1 |
| Venous thrombosis            | 2 |
| Pleural effusion             | 3 |
| Hypotension                  | 1 |
| Tako-Tsubo syndrome          | 1 |
**Liver**

| Complication               | Count |
|----------------------------|-------|
| Moderate liver failure     | 1     |

**Neurologic**

| Complication | Count |
|---------------|-------|
| Confusion     | 1     |

**Pain***

| Complication               | Count |
|----------------------------|-------|
| Diabetes decompensation    | 4     |
| Anemia                     | 1     |

---

*All the 7 reported complications were classified grade I according to the Dindo-Clavien classifications (i.e. any deviation from the normal postoperative course without the need for additional treatment)*
Table 4. Univariate Cox regression analysis evaluating pre-specified factors before surgery, associated with the occurrence of major endpoints after surgery

|                                | At least one grade 3 or more complication within 1 month after surgery (n=9) | At least one portal hypertension related complication£ within 3 months after surgery (n=16) | Death within 6 months after surgery (n=4) |
|--------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------------------|
|                                | HR                          | 95% CI                        | P value          | HR                          | 95% CI                        | P value          | HR                          | 95% CI                        | P value          |
| Age-adjusted comorbidity index | 1.103                       | 0.866                         | 1.404            | 0.427                       | 1.074                       | 0.913                         | 1.264            | 0.390                       |
| Extra-hepatic condition associated with INCPH | 1.387 | 0.331 | 5.810 | 0.654 | 3.973 | 1.129 | 13.982 | 0.032 |
| History of ascites* | 1.340 | 0.300 | 5.988 | 0.702 | 3.144 | 1.162 | 8.504 | 0.024 |
| Varices needing treatment** | 2.056 | 0.240 | 17.600 | 0.511 | 0.858 | 0.298 | 2.472 | 0.777 |
| Portal vein thrombosis | 2.104 | 0.363 | 12.196 | 0.407 | 0.750 | 0.170 | 3.304 | 0.704 |
| Serum bilirubin | 1.012 | 0.994 | 1.031 | 0.189 | 0.991 | 0.972 | 1.012 | 0.401 |
| Serum creatinine | 1.002 | 0.999 | 1.006 | 0.188 | 1.002 | 0.999 | 1.005 | 0.112 |
| Major surgery | 0.556 | 0.138 | 2.242 | 0.409 | 0.634 | 0.236 | 1.704 | 0.366 |
| Emergency procedure | 2.920 | 0.712 | 11.981 | 0.137 | 1.676 | 0.581 | 4.830 | 0.339 |

This article is protected by copyright. All rights reserved.
| Unfavorable outcome after surgery$ (n=23) | HR   | 95% CI    | P value |
|------------------------------------------|------|-----------|---------|
| Age-adjusted comorbidity index           | 1.099| 0.963     | 1.254   | 0.163 |
| Extra-hepatic condition associated with INCPH | 2.410| 0.939     | 6.186   | 0.067 |
| History of ascites*                      | 3.892| 1.650     | 9.180   | 0.002 |
| Varices needing treatment**              | 1.007| 0.390     | 2.598   | 0.989 |
| Portal vein thrombosis                   | 1.425| 0.479     | 4.237   | 0.524 |
| Serum bilirubin                          | 0.999| 0.985     | 1.014   | 0.901 |
| Serum creatinine                         | 1.003| 1.000     | 1.005   | 0.056 |
| Major surgery                            | 0.851| 0.356     | 2.032   | 0.716 |
| Emergency procedure                      | 2.136| 0.865     | 5.276   | 0.100 |

*History of ascites at surgery was defined either as a previous history of ascites that was controlled with diuretics at the time of surgery, or clinically detected ascites at surgery.

** Medium/large esophageal and/or gastric varices or history of variceal bleeding or history of endoscopic band ligation and/or glue
Portal hypertension-related complications were defined as any of decompensation ascites, hepatic encephalopathy, significant portal hypertension related bleeding, acute kidney injury, or spontaneous bacterial peritonitis occurring within 3 months after surgical intervention. Decompensation of ascites was defined as follows: (i) in patients without ascites, onset of clinically detectable ascites, confirmed by ultrasonography; (ii) in patients with previous ascites not requiring paracentesis, ascites requiring two or more paracentesis within 3 months following surgery, or requiring a TIPSS.

An unfavorable outcome after surgery was defined as either post-operative complication grade ≥3 within one month after surgery, or portal-hypertension related complications within 3 months after surgery or death within 6 months after surgery.

Abbreviations: HR, Hazard ratio; CI, confidence interval, INCPH, idiopathic noncirrhotic portal hypertension

Bold indicates significant associations.
Table 5. Characteristics of the 4 patients who died within 6 months after surgery

| Patient’s features at surgery | PATIENT 7 | PATIENT 8 | PATIENT 20 | PATIENT 41 |
|------------------------------|-----------|-----------|------------|------------|
| Age, years                   | 73        | 65        | 51         | 66         |
| Gender                       | Male      | Male      | Male       | Male       |
| Age-adjusted Charlson        | 8         | 6         | 9          | 8          |
| comorbidity index            |           |           |            |            |
| ASA score                    | 3         | 3         | 3          | 4          |
| Extra-hepatic condition      | Previous renal transplantation | None | None | Recurrent abdominal infection |
| associated with INCPH        | Azathioprine |         |            | NOD2 mutation |
| Ascites                      | None      | Tense     | Diuretic-sensitive ascites | Tense |
| History of variceal bleeding | No        | No        | Yes        | Yes        |
| Esophageal varices           | Medium-size | Absence   | Medium-size | Medium-size |
| Portal vein thrombosis       | No        | No        | No         | No         |
| Platelet count, x10^9/l      | 99        | 273       | 144        | 52         |
| INR                          | 1         | 1         | 0.94       | 1.16       |
| Serum bilirubin, µmol/l      | 16        | 6         | 8          | 8          |
| Serum creatinine, µmol/l     | 533       | 300       | 552        | 143        |
| MELD                         | 14        | 12        | 14         | 9          |
| Surgery                      |           |           |            |            |
| TIPSS performed before       | No        | Yes       | No         | No         |
| surgery                      |           |           |            |            |
| Surgical intervention        | Renal re- | Peritoneal | Nephrectomy | Alfadump® |
|                              | transplantation | catheter | placement   | implantation |
| Indication                   | End-stage renal failure | Refractory ascites | Fistula after renal biopsy | Refractory ascites |
| Post-operative outcome       |           |           |            |            |
| Occurrence of portal-        | Yes       | No        | Yes        | No         |
| hypertension related         | Ascites   |            | Spontaneous |            |
| complication after surgery   |           |           | bacterial   |            |
| Other post-operative complication | Variceal bleeding | Hepatic encephalopathy | Spontaneous bacterial peritonitis | Leakage | Wound infection | Pleural infection | Tako-Tsubo syndrome | Acute kidney injury | None |
|----------------------------------|-------------------|------------------------|----------------------------------|--------|----------------|------------------|--------------------|---------------------|------|
| **Duration between surgery and death** | 5.7 months | 2.2 months | 4.3 months | 3.8 months |
| **Cause of death** | Variceal bleeding | Cardiac arrest | Pneumonia | Septic shock |

Abbreviations: ASA, American Society of Anesthesiologists; INCPH, idiopathic noncirrhotic portal hypertension; MELD, Model for End-Stage Liver Disease
